Eisenberg et al. further confirmed that both CD4 and CD8 T cells in the PBMCs of melanoma patients and tumor-infiltrating lymphocytes (TILs) that capture melanoma antigens show preferential reactivity and cytotoxicity against melanoma33. The gene discussed is CD4; the disease is neoplasm.